Acute phase response after zoledronic acid is associated with long-term effects on white blood cells

Calcified Tissue International

Volumn 93, Issue 3, 2013, Pages 249-252

  Rossini, Maurizio ^a   Adami, Silvano ^a,c   Viapiana, Ombretta ^a   Tripi, Gaia ^a   Zanotti, Roberta ^a   Ortolani, Riccardo ^b   Vella, Antonio ^b   Troplini, Sonila ^a   Gatti, Davide ^a  

^a UNIVERSITY OF VERONA   (Italy)

^b UNIVERSITY HOSPITAL OF VERONA   (Italy)

^c POLICLINICO BORGO ROMA   (Italy)

Author keywords

Acute phase response; Bisphosphonate; Eosinophil; T cell; White blood cell

Indexed keywords

ZOLEDRONIC ACID;

ACUTE PHASE RESPONSE; ADULT; AGED; ARTICLE; B LYMPHOCYTE; CD3+ T LYMPHOCYTE; CD4+ T LYMPHOCYTE; CD8+ T LYMPHOCYTE; CELL POPULATION; CLINICAL ARTICLE; DRUG EFFECT; DRUG SAFETY; EOSINOPHIL COUNT; FEMALE; HUMAN; HUMAN CELL; LEUKOCYTE COUNT; LONG TERM CARE; LYMPHOCYTE COUNT; MONOCYTE; NATURAL KILLER CELL; NEUTROPHIL COUNT; PRIORITY JOURNAL; SIDE EFFECT;

ACUTE-PHASE REACTION; ADMINISTRATION, ORAL; AGED; AGED, 80 AND OVER; BONE DENSITY CONSERVATION AGENTS; DIPHOSPHONATES; EOSINOPHILS; FEMALE; HUMANS; IMIDAZOLES; LEUKOCYTE COUNT; LEUKOCYTES; LYMPHOCYTES; MIDDLE AGED; OSTEOPOROSIS; OSTEOPOROSIS, POSTMENOPAUSAL; RECEPTORS, ANTIGEN, T-CELL, GAMMA-DELTA; T-LYMPHOCYTE SUBSETS; TIME FACTORS;

EID: 84882456142     PISSN: 0171967X     EISSN: 14320827     Source Type: Journal    
DOI: 10.1007/s00223-013-9750-6     Document Type: Article

References (20)

1. Adami S, Bhalla AK, Dorizzi R, Montesanti F, Rosini S, Salvagno G, Lo Cascio V (1987) The acute-phase response after bisphoshonate administration. Calcif Tissue Int 41:326-333
2. Schweitzer DH, Oostendorp-van de Ruit M, Van der Pluijm G, Lowik CW, Papapoulos SE (1995) Interleukin-6 and the acute phase response during treatment of patients with Paget's disease with the nitrogen-containing bisphosphonate dimethyl-amino-hydroxy-propylidene bisphosphonate. J Bone Miner Res 10:956-962
3. Kunzmann V, Bauer E, Wilhelm M (1999) Gamma/delta T-cell stimulation by pamidronate. N Engl J Med 340:737-738
4. Roelofs AJ, Jauhiainen M, Monkkonen H, Rogers MJ, Monkkonen J, Thompson K (2009) Peripheral blood monocytes are responsible for gamma delta T cell activation induced by zoledronic acid through accumulation of IPP/DMAPP. Br J Haematol 144:245-250
5. Miyagawa F, Tanaka Y, Yamashita S, Minato N (2001) Essential requirement of antigen presentation by monocyte lineage cells for the activation of primary human gamma delta T cells by aminobisphosphonate antigen. J Immunol 166:5508-5514
6. Rossini M, Adami S, Viapiana O, Ortolani R, Vella A, Fracassi E, Gatti D (2012) Circulating γδ T cells and the risk of acute-phase response after zoledronic acid administration. J Bone Miner Res 27:227-230
7. Welton JL, Morgan MP, Martí S, Stone MD, Moser B, Sewell AK, Turton J, Eberl M (2013) Monocytes and γδ T cells control the acute phase response to intravenous zoledronate: insights from a phase IV safety trial. J Bone Miner Res 28:464-471
8. Rossini M, Adami S, Viapiana O, Fracassi E, Ortolani R, Vella A, Zanotti R, Tripi G, Idolazzi L, Gatti D (2012) Long-term effects of amino- bisphosphonates on circulating gammadelta T cells. Calcif Tissue Int 91:395-399
9. Kalyan S, Quabius ES, Wiltfang J, Mönig H, Kabelitz D (2013) Can peripheral blood γδ T cells predict osteonecrosis of the jaw? An immunological perspective on the adverse drug-effects of aminobisphosphonate therapy. J Bone Miner Res 28:728-735
10. Hayday AC (2009) Gammadelta T cells and the lymphoid stress-surveillance response. Immunity 31:184-196
11. Strid J, Roberts SJ, Filler RB, Lewis JM, Kwong BY, Schpero W, Kaplan DH, Hayday AC, Girardi M (2008) Acute upregulation of an NKG2D ligand promotes rapid reorganization of a local immune compartment with pleiotropic effects on carcinogenesis. Nat Immunol 9:146-154
12. Tanaka Y, Morita CT, Tanaka Y, Nieves E, Brenner MB, Bloom BR (1995) Natural and synthetic non-peptide antigens recognized by human gamma delta T cells. Nature 375:155-158
13. Dieli F, Gebbia N, Poccia F, Caccamo N, Montesano C, Fulfaro F, Arcara C, Valerio MR, Meraviglia S, Di Sano C, Sireci G, Salerno A (2003) Induction of γδ T-lymphocyte effector functions by bisphosphonate zoledronic acid in cancer patients in vivo. Blood 102:2310-2311
14. Lymperi S, Ersek A, Ferraro F, Dazzi F, Horwood NJ (2011) Inhibition of osteoclast function reduces hematopoietic stem cell numbers in vivo. Blood 117:1540-1549
15. Van den Wyngaert T, Wouters K, Huizing MT, Vermorken JB (2011) RANK ligand inhibition in bone metastatic cancer and risk of osteonecrosis of the jaw (ONJ): non bis in idem? Support Care Cancer 19:2035-2040
16. Humbles AA, Lloyd CM, McMillan SJ, Friend DS, Xanthou G, McKenna EE, Ghiran S, Gerard NP, Yu C, Orkin SH, Gerard C (2004) A critical role for eosinophils in allergic airways remodeling. Science 305:1776-1779
17. Cheung PF, Wong CK, Lam CW (2008) Molecular mechanisms of cytokine and chemokine release from eosinophils activated by IL-17A, IL-17F, and IL-23: implication for Th17 lymphocytes-mediated allergic inflammation. J Immunol 180:5625-5635
18. Kamiya N, Suzuki H, Endo T, Takano M, Yano M, Naoi M, Nishimi D, Kawamura K, Imamoto T, Ichikawa T (2011) Additive effect of zoledronic acid on serum prostate-specific antigen changes for hormone-sensitive prostate cancer patients with bone metastasis treated by combined androgen blockade. Int J Urol 19:169-173
19. Rennert G, Pinchev M, Rennert HS, Gruber SB (2011) Use of bisphosphonate and reduced risk of colorectal cancer. J Clin Oncol 29:1146-1150
20. Colón-Emeric CS, Mesenbrink P, Lyles KW, Pieper CF, Boonen S, Delmas P, Eriksen EF, Magaziner J (2010) Potential mediators of the mortality reduction with zoledronic acid after hip fracture. J Bone Miner Res 25:91-97